News

Data show that its nasal candidate drug Foralumab can downregulate inflammatory responses in the cerebrospinal fluid of patients with non-active secondary progressive multiple sclerosis with underlying disability progression, while upregulating neuroprotective pathways. In addition, the effect of this drug is correlated with a reduction in microglial activation as observed by positron emission tomography. These findings provide new insights into the therapeutic mechanism of Foralumab. The study suggests that this therapy may bring new hope to patients with this difficult-to-treat form of multiple sclerosis by modulating the immune environment of the central nervous system.

This series of measures aims to optimize the company's capital structure and enhance shareholder value. Through stock buybacks and capital returns, the company plans to efficiently return excess cash to investors. At the same time, the share consolidation transaction helps to simplify the equity structure. These actions fully demonstrate Thomson Reuters' robust financial position and confidence in future development.

The company emphasizes that it will continue to advance its established strategic direction, striving to seize long-term development opportunities and will not alter its set path due to short-term market fluctuations. This stance demonstrates the management's confidence in the company's future prospects and its firm commitment to value creation.